Clinical trial
Open Label, Phase 2 Study for Evaluating the Feasibility, Safety and Efficacy of Psychotherapy Assisted Psilocybin for Treatment of Severe Obsessive Compulsive Disorder (OCD) in Drug and/or Psychotherapy Resistant Patients.
NCT04882839 is registered in ClinicalTrials.gov with Beersheva Mental Health Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Open Label, Phase 2 Study for Evaluating the Feasibility, Safety and Efficacy of Psychotherapy Assisted Psilocybin for Treatment of Severe Obsessive Compulsive Disorder (OCD) in Drug and/or Psychotherapy Resistant Patients.
- Lead sponsor
- Beersheva Mental Health Center
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- November 25, 2024
- Completion date
- June 1, 2027
- Enrollment
- 15 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.